New Device Measures How Much Breast Milk a Baby Is Getting
The device could help ease any stress or concern about whether their baby is eating enough.
Until the device is on the market, there are several other ways to make sure your baby is getting enough nourishment.Breast and chestfeeding offers countless benefits for mom and baby, but one aspect of nursing causes many parents intense stress. I mean, who among us hasn't worried that our baby isn't getting enough breast milk?
While there are ways to determine if your baby is being properly nourished, like counting diaper output, researchers at Northwestern University felt there must be an easier and more updated method. So, they developed a device that uses sensors to measure exactly how much breast milk a baby is drinking.
It's important to note that the sensors are not available at the moment, but the hope is that the technology will be at new parents' disposal in a few years.
Lead researcher Daniel Robinson, MD MSc, an associate professor of pediatrics at Northwestern University Feinberg School of Medicine, explains to Parents that the device was designed to help health care professionals manage the nutritional needs of preterm and sick infants in the NICU. Their goal is also to reduce stress for breastfeeding parents and avoid the cumbersome use of pre- and post-feed weighing of infants.
'A mother would place a wireless sensor on the breast,' Robinson explains about how the device functions. 'Technically, the sensor is measuring a change in bioimpedance as the infant pulls milk out of the breast. The signal changes as the milk is expressed and breast tissue changes.'
Then, that information would be sent via Bluetooth to a smartphone, so parents can keep track of their baby's breastmilk intake.
Until the device is operational, if you are not a technophile, or if you can be technically challenged (timidly raises hand), Abrie McCoy, an IBCLC with SimpliFed, wants new parents to remember their bodies were made to breastfeed efficiently!
That said, McCoy emphasizes, 'It's completely normal to wonder if your baby is getting enough to eat.'
'While these concerns are valid, take a deep breath and trust in your body and your ability to nourish your baby,' she advises new parents.
McCoy says instead of focusing on finding an exact measurement of breast milk intake, parents should look for the signs of a successful feed.
Signs of a successful feeding routine include:
Your newborn is nursing often. McCoy says a new baby will nurse at least 8 to 10 times in a 24-hour period.
Baby is making wet and dirty diapers. 'From day 3 to 1 month old, your baby should have at least six wet diapers and three dirty diapers per day,' McCoy says. 'These numbers tell us your baby is well-hydrated and getting the nourishment they need.'
Baby continues to grow and thrive. This is a key indication that your baby is receiving the nourishment required.
Baby is experiencing a steady increase in head circumference, length, and weight. These trends are measured at your baby's well visits.
McCoy encourages new parents to support their bodies in providing nourishment to their babies, and following the baby's lead when it comes to showing hunger cues. Don't forget to relax and reach out for help from a lactation specialist or your child's pediatrician if you have concerns.
Read the original article on Parents
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Dental Imaging Market Worth US$4.69 billion by 2030 with 7.5% CAGR
DELRAY BEACH, Fla., July 30, 2025 /PRNewswire/ -- The global Dental Imaging Market, valued at US$3.08 billion in 2024 stood at US$3.26 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2030, culminating in a forecasted valuation of US$4.69 billion by the end of the period. The dental imaging market is experiencing growth due to ongoing innovations in imaging technologies that provide precise results. Several factors contribute to this market expansion, including the increasing number of dental professionals, a rising demand for aesthetic treatments, and a higher prevalence of dental caries and periodontal diseases that require effective diagnostic tools. Patients and dental professionals alike prefer early and accurate disease diagnosis, which further drives the demand for dental imaging. Additionally, there is a growing need for accurate and efficient diagnostic tools, such as intraoral cameras. This factor, along with the increasing affordability of imaging systems, has led to greater adoption of dental imaging technologies in dental hospitals worldwide. Download PDF Brochure: Browse in-depth TOC on "Dental Imaging Market" 150 - Tables45 - Figures250 - Pages By product, the dental imaging market has been divided into two main categories: extraoral and intraoral imaging systems. Among the extraoral imaging systems segment, panoramic imaging systems represented the largest share in 2024. This significant share is largely due to its extensive applications in general dentistry, implantology, endodontics, and periodontics, where it is used for initial patient assessments and to enhance accuracy in treatment planning. By application, the market has been segmented based on application into five main categories: implantology, endodontics, oral & maxillofacial surgery, orthodontics, and other applications. Among these segments, implantology represented the largest share in 2024. As people become more focused on aesthetics, the demand for implants is increasing. The placement of implants requires a detailed understanding of bone density, nerve pathways, and anatomical structures, which has led to a growing need for 3D imaging. Cone beam computed tomography (CBCT) is in high demand for implant planning, as it assists surgeons during surgery. By end user, the dental imaging market is segmented based on end users into three categories: dental clinics & hospitals, dental diagnostic centers, and dental academic & research institutes. In 2024, the dental clinics & hospitals segment held the largest market share. This dominance can be attributed to several factors, including the growing affordability of imaging systems, an increasing need for accurate and rapid diagnoses, and heightened awareness among patients. By geography, The Asia Pacific region is anticipated to experience the highest growth during the forecast period, mainly due to the increasing demand for dental imaging technology in countries such as China, India, Japan, and South Korea. As a result, many global companies are concentrating on enhancing their research and development capabilities as well as expanding their distribution networks in this region. In 2024, North America held the largest share of the dental imaging market, followed by Europe. Request Sample Pages : The prominent players in the dental imaging market include Envista Holdings Corporation (US), Planmeca Oy (Finland), ACTEON (UK), DENTSPLY SIRONA Inc. (US), Carestream Dental LLC (US), VATECH (South Korea), Owandy Radiology, Inc. (France), DÜRR DENTAL AG (Germany), Midmark Corporation (US), Genoray Co., Ltd. (South Korea), Asahi Roentgen Co., Ltd. (Japan), 3Shape (Denmark), PreXion, Inc. (US), Ningbo Runyes Medical Instrument Co. Ltd.(China), Cefla Medical Equipment (Italy), Apteryx Imaging (Canada), Yoshida Dental Mfg. Co., Ltd. (Japan), Align Technology Inc. (US), J. MORITA CORP (Japan), and FONA Srl (Italy). Envista Holdings Corporation (US): Envista Holdings Corporation (US) is a leader in the global dental imaging market. As a prominent global dental products company, Envista has a strong presence in dental imaging, primarily through its flagship brand, DEXIS. The company offers a comprehensive range of imaging solutions, including intraoral sensors, 3D CBCT systems, panoramic and cephalometric units, as well as AI-powered diagnostic software. To increase its share in the dental imaging market, Envista continuously focuses on product development and innovation. In February and May 2024, DEXIS launched the DEXIS Digital and DEXIS Ti2 intraoral scanners, demonstrating the company's commitment to frequent product advancements. DENTSPLY SIRONA (US) DENTSPLY SIRONA (US) held the second-leading position in the dental imaging market and is recognized as one of the top players in the industry, serving numerous sectors across a wide geographic area. Its emphasis on research and development (R&D) allows it to expand its product portfolio and diversify its offerings. In September 2024, the company introduced Primescan 2, a new product that enables users to scan directly to the cloud from any internet-connected device. VATECH (South Korea) VATECH (South Korea) is a leader in dental imaging technologies, specializing in a comprehensive range of X-ray systems, including intraoral and panoramic units, as well as high-end CBCT scanners and complementary software solutions. In 2024, the company intensified its focus on AI innovation, introducing advanced features such as 3D CBCT segmentation for teeth, roots, and nerves, along with image enhancement capabilities that include noise reduction and resolution improvements. For more information, Inquire Now! Related Reports: Dental Equipment Market Dental Implants and Prosthetics Market Dental Bone Graft Substitute Market Dental Digital X-ray Market Dental Bone Graft Substitute Market Get access to the latest updates on Dental Imaging Companies and Dental Imaging Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
3 minutes ago
- Yahoo
Optometrist Dr. Selina McGee Highlights the Dry Eye Epidemic and New Skincare Solutions with YourUpdateTV
Dr. Selina McGee Teams with OPTASE to Discuss the Warning Signs of Dry Eye Disease and Treatment Options NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Dry eye disease affects millions and is increasingly driven by prolonged screen time, dry indoor environments, and everyday beauty products that can inadvertently irritate or damage the eyes. Nearly half of Americans experience symptoms such as stinging, burning, fluctuating vision, or gritty eyes, often dismissing them as normal fatigue. Untreated dry eyes can progress to inflammation, damage to the eye's surface, and even long-term issues with tear production. Recently, Optometrist and Founder of Bespoke Vision, Dr. Selina McGee teamed up with OPTASE on a nationwide media tour to discuss the warning signs for dry eyes and treatment options that can help. One of the most overlooked triggers of dry eye is screen time. Prolonged staring at screens reduces both the frequency and completeness of blinking, disrupting the tear film and accelerating evaporation. Combined with dry indoor air or air conditioning, this can lead to persistent eye discomfort throughout the day. Dr. McGee also highlighted the impact of makeup and skincare products on eye health. Many common formulations contain preservatives, synthetic fragrances, or surfactants that can migrate into the eyes, exacerbating dryness and inflaming the glands responsible for keeping them lubricated and comfortable. For gentle daily care, Dr. McGee recommended the OPTASE® LIFE product line, designed specifically for dry and sensitive skin around the eyes. The Sensitive Eye Makeup Remover features just seven ingredients—including Ionized Water, Hyaluronic Acid, Panthenol, and Manuka Honey—to cleanse thoroughly without irritating the eye area. The Sensitive Eye Daily Renewal Cream contains 13 ingredients, including Glycerin and Vitamin E, and offers 48 hours of hydration while helping restore the skin's natural barrier and reducing the appearance of fine lines. For daytime relief, OPTASE® Intense Drops provide fast-acting, preservative-free moisture, ideal for long workdays or extended digital use. All products are available at with 20% off OPTASE® LIFE products using the code LIFE20 at checkout. About Dr. Selina McGee:Dr. Selina McGee, OD, FAAO, is a nationally acclaimed optometrist and the founder of BeSpoke Vision in Edmond, Oklahoma. Known for her expertise in dry eye disease, aesthetics, and ocular surface health, Dr. McGee blends advanced medical training with a personalized, patient-first approach to eye care. She is a Fellow of the American Academy of Optometry and serves on numerous professional advisory boards. Dr. McGee is passionate about educating patients and providers alike on the impact of lifestyle, beauty routines, and technology on long-term eye health. * YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of OPTASE. Dante MuccigrossoDirector of Media Integration & Client ReportingE: dantem@ 973.524.0104 A video accompanying this release is available at
Yahoo
3 minutes ago
- Yahoo
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia. "This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development," said Frank Stonebanks, Chief Executive Officer of EuMentis. "EM–221 is more than a single asset—it represents a pipeline in a product with potential applications across multiple neuropsychiatric and neurodevelopmental conditions. As we enter this next phase, we're excited by the opportunity to unlock significant therapeutic and commercial value in schizophrenia and beyond, supported by a world-class team and leading scientific collaborators." EM-221 is targeting PDE10A, a key intracellular enzyme that regulates dopamine and glutamate signaling in brain regions implicated in schizophrenia. Unlike traditional antipsychotics that broadly block dopamine receptors and are associated with serious side effects such as weight gain, movement disorders, and sedation, PDE10A inhibition offers a more targeted mechanism that modulates these pathways without direct receptor antagonism. "We are very excited to receive IND clearance from the FDA for schizophrenia, which is a serious, lifelong disorder affecting nearly 4 million adults and adolescents in the U.S. alone," said Dr. Randall Marshall, Chief Medical Officer of EuMentis. "There is a wealth of data suggesting that a PDE10A inhibitor can benefit individuals with schizophrenia as a more effective, safer, and better-tolerated therapy. We look forward to initiating our Phase 2 study of EM-221 later this year." EM–221 is a next-generation, selective PDE10A inhibitor designed to maximize efficacy while minimizing off-target effects. Preclinical and phase 1 clinical studies suggest EM–221 may offer superior tolerability and a broader therapeutic window, positioning it as a potential best-in-class treatment for both the positive and negative symptoms of schizophrenia—a critical gap left unaddressed by current therapies. "Despite decades of use, current dopamine receptor-blocking antipsychotic medications remain limited in their tolerability and effectiveness which make them unacceptable to many patients," said Dr. John Krystal, Robert L. McNeil, Jr. Professor of Translational Research and Chair of Psychiatry at Yale School of Medicine. "The PDE10A mechanism represents an important and innovative approach to modulating dopaminergic and glutamatergic signaling in the brain. I'm encouraged by the potential of EM–221 to offer a new therapeutic option for patients who urgently need safer and more effective treatments." About EM-221 EuMentis is building a pipeline-in-a-product around EM-221. EM-221 is an innovative product that targets the phosphodiesterase 10A enzyme, uniquely concentrated in the brain's striatum, to enhance cyclic nucleotide signaling and balance dopamine pathways. Unlike traditional antipsychotics, it offers the potential to address not only the positive symptoms like hallucinations but also the challenging negative symptoms—such as social withdrawal, blunted emotions and difficulty planning—that often persist untreated. EM-221 has been cleared by the U.S. FDA for Phase 2 evaluation, and the company expects to begin dosing in its first clinical trial in the second half of 2025. About EuMentis Therapeutics EuMentis is a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach will enable its therapies to achieve better efficacy and tolerability, with the goal to deliver improved outcomes for patients. The Company's lead product, EM-221, is a potentially groundbreaking advancement in schizophrenia treatment, with a new, differentiated PDE10A inhibitor. Developed through years of rigorous research, this breakthrough heralds a new era of hope, aiming to improve overall quality of life for those affected by schizophrenia with a novel mechanism that's both precise and promising. EuMentis is headquartered in San Diego, CA. For more information, please visit and engage with us on LinkedIn. Media ContactAmy ConradJuniper Pointamy@ Company ContactFrank StonebanksCEOfstonebanks@ View original content to download multimedia: SOURCE EuMentis Therapeutics, Inc. Sign in to access your portfolio